A large cohort study yesterday of nirsevimab (Beyfortus) use during the 2024-25 respiratory syncytial virus (RSV) season ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback